Drugs / n-3 polyunsaturated fatty acids
n-3 polyunsaturated fatty acids
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03350906 | Jan 2018 → Dec 2021 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00317707 | Feb 2004 → Oct 2011 | cardiovascular disorder | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 3 | NCT00336336 | Aug 2002 → Apr 2008 | heart failure | Gruppo di Ricerca GISSI | Completed | No outcome recorded |
| Phase 3 | NCT00000473 | Jul 1989 → Jun 1994 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | n-3 polyunsaturated fatty acids | “To determine whether a dietary supplement of n-3 polyunsaturated fatty acids (PUFAs) derived from fish oil would decrease the restenosis rate in patients undergoing...” NCT00000473 ↗3“Treatment with n-3 polyunsaturated fatty acids improves prognosis after myocardial infarction” PMID 20509875 ↗ May 2010 “Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure” PMID 18757090 ↗ Aug 2008 |
| Known as | n-3 PUFA | “The antiarrhythmic effects of n-3 polyunsaturated fatty acids (n-3PUFA) in ischemic heart disease have been demonstrated” PMID 21315217 ↗ Feb 2011 |
| Known as | omega-3 fatty acids | “suppressing chronic inflammation using omega-3 fatty acids (n3-PUFA) restores skeletal muscle function and exercise responsiveness in older adults.” NCT03350906 ↗ |
| Modality | Other / unclassified | “Polyunsaturated fatty acids of marine origin (n-3 PUFA)” NCT00317707 ↗ |
| Route | Oral | “1 g die per os” NCT00336336 ↗ |